Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
06
03
2021
pubmed:
13
3
2021
medline:
13
3
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
Treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) continues to evolve expeditiously. This retrospective study investigated real-world treatment patterns and EGFR mutation testing in patients with EGFRm advanced NSCLC in Belgium. Data were extracted from medical records of adults diagnosed with EGFRm locally advanced/metastatic NSCLC between 1 September 2015 and 31 December 2017. Patients were followed retrospectively from diagnosis until 1 September 2018, end of clinical activity or death. Data on demographics, patient outcomes and disease characteristics, treatment patterns and EGFR mutation testing at diagnosis and progression were analyzed descriptively. A total of 141 patients were enrolled. At diagnosis, median age was 69 years, 63.1% were female, 88.7% had metastatic disease, 94.3% had adenocarcinoma histology, 76.6% had ECOG 0/1, 70.9% had common EGFR mutations and 29.1% had only rare mutations. In first line, 73.8% of patients received first/second-generation EGFR-tyrosine kinase inhibitors (1G/2G EGFR-TKIs), while 21.9% received other systemic treatments. Among 61 patients progressing on and discontinuing a first 1G/2G EGFR-TKI, 45 (73.8%) received subsequent systemic treatment while 16 (26.2%) did not; 20 (32.8%) received osimertinib. Among 65 patients progressing on a first 1G/2G EGFR-TKI, 47 (72.3%) were tested for T790M, of whom 25 (53.2%) were positive. These real-world data from Belgium show that a substantial fraction of patients with EGFRm NSCLC do not receive 1G/2G EGFR-TKIs in first line and do not receive subsequent systemic treatment after progression on 1G/2G EGFR-TKIs. Only a third receive osimertinib upon progression on 1G/2G EGFR-TKIs. These observations should be considered in first-line treatment decisions. ClinicalTrials.gov: NCT03761901-December 3, 2018.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) continues to evolve expeditiously.
OBJECTIVES
OBJECTIVE
This retrospective study investigated real-world treatment patterns and EGFR mutation testing in patients with EGFRm advanced NSCLC in Belgium.
METHODS
METHODS
Data were extracted from medical records of adults diagnosed with EGFRm locally advanced/metastatic NSCLC between 1 September 2015 and 31 December 2017. Patients were followed retrospectively from diagnosis until 1 September 2018, end of clinical activity or death. Data on demographics, patient outcomes and disease characteristics, treatment patterns and EGFR mutation testing at diagnosis and progression were analyzed descriptively.
RESULTS
RESULTS
A total of 141 patients were enrolled. At diagnosis, median age was 69 years, 63.1% were female, 88.7% had metastatic disease, 94.3% had adenocarcinoma histology, 76.6% had ECOG 0/1, 70.9% had common EGFR mutations and 29.1% had only rare mutations. In first line, 73.8% of patients received first/second-generation EGFR-tyrosine kinase inhibitors (1G/2G EGFR-TKIs), while 21.9% received other systemic treatments. Among 61 patients progressing on and discontinuing a first 1G/2G EGFR-TKI, 45 (73.8%) received subsequent systemic treatment while 16 (26.2%) did not; 20 (32.8%) received osimertinib. Among 65 patients progressing on a first 1G/2G EGFR-TKI, 47 (72.3%) were tested for T790M, of whom 25 (53.2%) were positive.
CONCLUSION
CONCLUSIONS
These real-world data from Belgium show that a substantial fraction of patients with EGFRm NSCLC do not receive 1G/2G EGFR-TKIs in first line and do not receive subsequent systemic treatment after progression on 1G/2G EGFR-TKIs. Only a third receive osimertinib upon progression on 1G/2G EGFR-TKIs. These observations should be considered in first-line treatment decisions.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov: NCT03761901-December 3, 2018.
Identifiants
pubmed: 33710523
doi: 10.1007/s40801-021-00243-w
pii: 10.1007/s40801-021-00243-w
pmc: PMC8128953
doi:
Banques de données
ClinicalTrials.gov
['NCT03761901']
Types de publication
Journal Article
Langues
eng
Pagination
141-152Investigateurs
Lynn Decoster
(L)
Paul Germonpré
(P)
Elke Govaerts
(E)
Stéphane Holbrechts
(S)
Marc Lambrechts
(M)
Sebahat Ocak
(S)
Veerle Surmont
(V)
Oswald Van Cutsem
(O)
Références
Oncotarget. 2017 Jan 3;8(1):1343-1353
pubmed: 27935868
Int J Mol Sci. 2019 Mar 21;20(6):
pubmed: 30901844
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542
pubmed: 31099633
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Thorac Cancer. 2018 Jul;9(7):856-864
pubmed: 29761660
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Expert Rev Mol Diagn. 2017 Dec;17(12):1089-1096
pubmed: 29057681
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
J Clin Oncol. 2011 Jul 20;29(21):2866-74
pubmed: 21670455
Oncotarget. 2018 Feb 4;9(36):24237-24247
pubmed: 29849936
Cancer Treat Rev. 2018 Jul;68:69-79
pubmed: 29883857
Clin Transl Oncol. 2017 Dec;19(12):1537-1542
pubmed: 28660482
Cancers (Basel). 2018 Aug 27;10(9):
pubmed: 30150518
Ann Oncol. 2015 Sep;26(9):1877-1883
pubmed: 26141208
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Ann Oncol. 2017 Nov 1;28(11):2715-2724
pubmed: 28945865
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Cells. 2018 Nov 15;7(11):
pubmed: 30445769
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
Curr Oncol. 2018 Jun;25(Suppl 1):S103-S114
pubmed: 29910653
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
J Clin Oncol. 2014 Nov 10;32(32):3673-9
pubmed: 25311215
J Thorac Oncol. 2018 Aug;13(8):1138-1145
pubmed: 29874546
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Arch Pathol Lab Med. 2018 Feb;142(2):163-167
pubmed: 29106293
Cancer Res Treat. 2019 Apr;51(2):502-509
pubmed: 29898592
ESMO Open. 2020 Nov;5(6):e001011
pubmed: 33148621
J Thorac Oncol. 2018 Mar;13(3):323-358
pubmed: 29396253
Front Pharmacol. 2019 Mar 12;10:230
pubmed: 30930778
Br J Cancer. 2014 Jan 7;110(1):55-62
pubmed: 24263064
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
Lung Cancer. 2014 Nov;86(2):170-3
pubmed: 25214431
Oncol Res. 2018 Aug 23;26(7):1031-1036
pubmed: 29321093
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168